We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Novel Biopsy Test Accurately Assesses Risk of Aggressive Disease in Early-Stage Prostate Cancer Patients

By LabMedica International staff writers
Posted on 30 Jan 2025

Prostate cancer ranks as the second most common cancer in men, the second leading cause of cancer-related deaths in men, and the fourth most prevalent cancer worldwide. More...

Diagnosing and managing prostate cancer often involves weighing the risks of aggressive disease against the potential side effects of treatment. Around 70% of prostate cancer cases are slow-growing and can be safely monitored with active surveillance, while 30% are more aggressive and require immediate treatment due to their high potential for recurrence. However, current diagnostic methods struggle to accurately distinguish between aggressive and low-risk cancer, leading to over-treatment. Many patients undergo unnecessary radical treatments, which can result in severe complications such as infections, incontinence, erectile dysfunction, and depression. A new biopsy test now offers improved risk assessment for prostate cancer recurrence, allowing for more informed treatment decisions.

OncoAssure Ltd. (Dublin, Ireland) has developed OncoAssure Prostate, a biopsy-based molecular test that helps identify patients with low-risk prostate cancer who can be safely managed with active surveillance, avoiding the significant lifelong side effects associated with more aggressive treatments. The test has been developed and optimized using a large, multi-center cohort and clinically validated in two independent international cohorts. A collaborative study showed that OncoAssure Prostate improves clinicians’ ability to predict aggressive cancer compared to using standard clinical and pathological data alone.

The study, published in BJUI Compass, demonstrated that incorporating OncoAssure Prostate results alongside traditional clinical and pathological information significantly enhances prognostic accuracy. Patients with higher OncoAssure Prostate risk scores were more likely to experience cancer recurrence, while those with lower risk scores were identified as suitable candidates for active surveillance. This prognostic test, which can accurately differentiate between aggressive and low-risk prostate cancers at the initial diagnosis, helps identify high-risk patients (about 20%) who would benefit from more intensive treatment, while providing low-risk patients with the reassurance that active surveillance is the best option for them.

"Our findings show that the OncoAssure Prostate test is a powerful tool that adds significant value to traditional clinical and pathological risk stratifiers," said Professor William Gallagher, Chief Scientific Officer, and co-founder, OncoAssure. "This enables better-informed decisions for prostate cancer treatment, potentially reducing overtreatment and optimizing outcomes."

“By accurately identifying patients at higher risk of aggressive disease, our test equips clinicians to tailor treatment plans that can improve patient outcomes,” added Des O’Leary, CEO and co-founder, OncoAssure. “OncoAssure Prostate is now validated for use at two key decision points along the Prostate Cancer pathway, namely post-biopsy and post-radical prostatectomy. This new data underpins the value of the test as we launch the product in the US this year.”

Related Links:
OncoAssure Ltd.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.